Aatish Garg1, Monica Khunger1, Sinziana Seicean2, Mina K Chung2, Patrick J Tchou3. 1. Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA. 2. Department of Cardiovascular Medicine, Heart & Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA. 3. Department of Cardiovascular Medicine, Heart & Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA. Electronic address: tchoup@ccf.org.
Abstract
OBJECTIVES: This study sought to compare the risk of thromboembolism after cardioversion within 48 h of atrial fibrillation (AF) onset in patients therapeutically versus not therapeutically anticoagulated. BACKGROUND: Although guidelines do not mandate anticoagulation for cardioversion within 48 h of AF onset, risk of thromboembolism in this group has been understudied. METHODS: Patients undergoing cardioversion within 48 h after AF onset were identified from a prospectively collected database and retrospectively reviewed to determine anticoagulation status and major thromboembolic events within 30 days of cardioversion. RESULTS: Among 567 cardioversions in 484 patients without therapeutic anticoagulation (mean CHA2DS2-VASc score, 2.3 ± 1.7), 6 had neurological events (1.06%), all in patients on aspirin alone. Among 898 cardioversions in 709 patients on therapeutic anticoagulation (mean CHA2DS2-VASc score, 2.6 ± 1.7; p = 0.017), 2 neurological events occurred (0.22%; OR: 4.8; p = 0.03), both off anticoagulation at the time of stroke. No thromboembolic events occurred in patients with CHA2DS2-VASc score <2 (p = 0.06) or in patients with postoperative AF. CONCLUSIONS: In patients with acute-onset AF, odds of thromboembolic complications were almost 5 times higher in patients without therapeutic anticoagulation at the time of cardioversion. However, no events occurred in post-operative patients and in those with CHA2DS2-VASc scores of <2, supporting the utility of accurate assessment of AF onset and risk stratification in determining the need for anticoagulation for cardioversion of AF <48 h in duration.
OBJECTIVES: This study sought to compare the risk of thromboembolism after cardioversion within 48 h of atrial fibrillation (AF) onset in patients therapeutically versus not therapeutically anticoagulated. BACKGROUND: Although guidelines do not mandate anticoagulation for cardioversion within 48 h of AF onset, risk of thromboembolism in this group has been understudied. METHODS:Patients undergoing cardioversion within 48 h after AF onset were identified from a prospectively collected database and retrospectively reviewed to determine anticoagulation status and major thromboembolic events within 30 days of cardioversion. RESULTS: Among 567 cardioversions in 484 patients without therapeutic anticoagulation (mean CHA2DS2-VASc score, 2.3 ± 1.7), 6 had neurological events (1.06%), all in patients on aspirin alone. Among 898 cardioversions in 709 patients on therapeutic anticoagulation (mean CHA2DS2-VASc score, 2.6 ± 1.7; p = 0.017), 2 neurological events occurred (0.22%; OR: 4.8; p = 0.03), both off anticoagulation at the time of stroke. No thromboembolic events occurred in patients with CHA2DS2-VASc score <2 (p = 0.06) or in patients with postoperative AF. CONCLUSIONS: In patients with acute-onset AF, odds of thromboembolic complications were almost 5 times higher in patients without therapeutic anticoagulation at the time of cardioversion. However, no events occurred in post-operative patients and in those with CHA2DS2-VASc scores of <2, supporting the utility of accurate assessment of AF onset and risk stratification in determining the need for anticoagulation for cardioversion of AF <48 h in duration.
Authors: John H Burton; David R Vinson; Kate Drummond; Tania D Strout; Henry C Thode; Jeff J McInturff Journal: Ann Emerg Med Date: 2004-07 Impact factor: 5.721
Authors: Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf Journal: N Engl J Med Date: 2011-08-10 Impact factor: 91.245
Authors: Morten Lock Hansen; Rikke Malene H G Jepsen; Jonas Bjerring Olesen; Martin Huth Ruwald; Deniz Karasoy; Gunnar Hilmar Gislason; Jim Hansen; Lars Køber; Steen Husted; Christian Torp-Pedersen Journal: Europace Date: 2014-09-17 Impact factor: 5.214
Authors: K E Juhani Airaksinen; Toni Grönberg; Ilpo Nuotio; Marko Nikkinen; Antti Ylitalo; Fausto Biancari; Juha E K Hartikainen Journal: J Am Coll Cardiol Date: 2013-07-10 Impact factor: 24.094
Authors: Brenton M Wong; Jeffrey J Perry; Wei Cheng; Bo Zheng; Kevin Guo; Monica Taljaard; Allan C Skanes; Ian G Stiell Journal: CJEM Date: 2021-03-14 Impact factor: 2.410